drugset / Trial / NCT02581345
Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis
RandomizedFactorialTriple-blindTreatment
Summary
The purpose of the study is to evaluate efficacy, safety, and immunogenicity of a proposed adalimumab biosimilar (M923) and Humira in participants with moderate to severe chronic plaque-type psoriasis.
Timeline
- Start
- 2015-09
- Primary completion
- 2017-04-04
- Completion
- 2017-04-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Adalimumab | Monoclonal antibody | — | — |
| Subject | M923 | Monoclonal antibody | — | — |